Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Sunvozertinib in Healthy Adults
NCT04909242Phase 1Completed
- Sponsor
- Dizal Pharmaceutical Co., Ltd.
- Start
- Apr 2021
- Primary completion
- Feb 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of sunvozertinib in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Dizal Pharmaceutical Co., Ltd. Primary endpoints: Number of participants that experience Adverse Events (AEs) and Serious Adverse Events (SAEs) at 14 days, Number of participants with clinically significant laboratory assessment abnormalities at 14 days and 3 more. Started Apr 2021; status: completed.
02
Drugs
sunvozertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04909242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04909242.